Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) VP Jason Pitofsky Sells 487 Shares

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) VP Jason Pitofsky sold 487 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total value of $521,090.00. Following the transaction, the vice president now directly owns 4,204 shares in the company, valued at $4,498,280. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Regeneron Pharmaceuticals Price Performance

REGN traded up $1.61 during trading on Wednesday, reaching $1,067.80. The stock had a trading volume of 502,528 shares, compared to its average volume of 471,543. The stock has a market cap of $117.66 billion, a PE ratio of 31.39, a PEG ratio of 2.32 and a beta of 0.13. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.51 and a current ratio of 5.96. Regeneron Pharmaceuticals, Inc. has a one year low of $769.19 and a one year high of $1,115.00. The business has a 50-day moving average of $1,047.01 and a 200-day moving average of $985.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 EPS for the quarter, beating analysts’ consensus estimates of $8.93 by $2.63. The business had revenue of $3.55 billion for the quarter, compared to analysts’ expectations of $3.38 billion. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The firm’s revenue was up 12.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $8.79 earnings per share. As a group, equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.45 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the company. JPMorgan Chase & Co. boosted their price objective on Regeneron Pharmaceuticals from $1,150.00 to $1,200.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. Morgan Stanley decreased their target price on Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an “overweight” rating for the company in a research report on Thursday, July 11th. Evercore ISI initiated coverage on Regeneron Pharmaceuticals in a research report on Tuesday, May 14th. They issued an “outperform” rating and a $1,150.00 target price for the company. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $1,152.00 target price on shares of Regeneron Pharmaceuticals in a research report on Thursday, June 27th. Finally, Wells Fargo & Company boosted their target price on Regeneron Pharmaceuticals from $1,125.00 to $1,200.00 and gave the company an “overweight” rating in a research report on Friday, August 2nd. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,097.05.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Prime Capital Investment Advisors LLC grew its stake in shares of Regeneron Pharmaceuticals by 35.5% during the fourth quarter. Prime Capital Investment Advisors LLC now owns 851 shares of the biopharmaceutical company’s stock valued at $747,000 after buying an additional 223 shares during the last quarter. Busey Bank increased its holdings in shares of Regeneron Pharmaceuticals by 0.8% in the fourth quarter. Busey Bank now owns 1,997 shares of the biopharmaceutical company’s stock worth $1,754,000 after buying an additional 16 shares during the period. Allspring Global Investments Holdings LLC increased its holdings in shares of Regeneron Pharmaceuticals by 54.1% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 52,299 shares of the biopharmaceutical company’s stock worth $45,934,000 after buying an additional 18,361 shares during the period. Turtle Creek Wealth Advisors LLC purchased a new position in shares of Regeneron Pharmaceuticals in the fourth quarter worth about $91,000. Finally, Sequoia Financial Advisors LLC increased its holdings in shares of Regeneron Pharmaceuticals by 75.1% in the fourth quarter. Sequoia Financial Advisors LLC now owns 2,099 shares of the biopharmaceutical company’s stock worth $1,844,000 after buying an additional 900 shares during the period. Institutional investors own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.